Frontline plc.
12.12.2024 22:30:00 CET | Globenewswire | Press release
FRO – 2024 Annual General Meeting
FRO – 2024 Annual General Meeting
Frontline plc (the “Company”) advises that the 2024 Annual General Meeting of the Shareholders of the Company was held on 12 December 2024 at 09:00 a.m. at Metis Tower, 28th October Avenue and Iakovou Tombazi Street, 4th floor, 3107 Limassol, Cyprus. The audited consolidated financial statements for the Company for the year ended 31 December 2023 were presented to the Meeting.
In addition, the following resolutions were passed:
- To re-elect John Fredriksen as a Director of the Company.
- To re-elect James O’Shaughnessy as a Director of the Company.
- To re-elect Ola Lorentzon as a Director of the Company.
- To re-elect Cato Stonex as a Director of the Company.
- To re-elect Steen Jakobsen as a Director of the Company.
- To elect Ørjan Svanevik as a Director of the Company.
- To elect Dr. Maria Papakokkinou as a Director of the Company.
- To re-appoint PricewaterhouseCoopers of Limassol, Cyprus as auditors and to authorise the Directors to determine their remuneration.
- To approve the remuneration of the Company’s Board of Directors of a total amount of fees not to exceed USD 600,000 for the year ended December 31, 2024.
- To approve with effect from 12:00 p.m. (Cyprus time) on 12th December, 2024 (the “Effective Date”) and for a period of twelve (12) calendar months from the Effective Date the exclusion of the shareholders’ right of pre-emption with respect to any offer by the Company to the public against cash consideration, as may be decided by the Board of Directors from time to time, of a maximum of 377,377,111 ordinary shares of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company at a subscription price which shall be determined by the Board of Directors not lower than USD 1 per share.
- To approve with effect from 12:00 pm (Cyprus time) on 12th December, 2024 (the “Effective Date”) and for a period of twelve (12) calendar months from the Effective Date the exclusion of the shareholders’ right of pre-emption with respect to any offer by the Company to the public for cash consideration as may be decided by the Board of Directors from time to time, of a maximum of 377,377,111 debentures or other securities convertible into ordinary shares of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company or options or other securities carrying the right to subscribe for ordinary shares of the Company of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company at a subscription price which shall be determined by the Board of Directors not lower than USD 1 per security.
- To approve on an advisory vote basis the Company’s Remuneration Report for the year ended December 31st, 2023 pursuant to the provisions of the Encouragement of Long-Term Shareholders Engagement Law 111(I)/2021.
12 December 2024
The Board of Directors
Frontline plc
Limassol, Cyprus
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S13.6.2026 18:45:00 CEST | Press release
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
King Faisal Specialist Hospital & Research Centre13.6.2026 15:57:00 CEST | Press release
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
Chery Group13.6.2026 11:39:45 CEST | Press release
FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch
Hotel Belles Rives13.6.2026 00:11:17 CEST | Press release
Julian Barnes Named Laureate of the 2026 Fitzgerald Prize
Sanofi Winthrop Industrie13.6.2026 00:09:43 CEST | Press release
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom